Global CDMO Ajinomoto Bio-Pharma Services has become the first organization to position itself as a Translation to Industry Collaborator within CMAC, a world-leading center for medicines manufacturing at the University of Strathclyde.

Joining a world-renowned research Centre with organizations such as AstraZeneca, Chiesi, Lilly, Pfizer, Roche, Sanofi, Takeda, UCB, and 20+ technology companies, the collaboration with Aji Bio-Pharma will support CMAC to accelerate the digital transformation of CMC.

As a CDMO, Aji Bio-Pharma plays a significant role in the pharmaceutical industry. Its ambition to enhance expertise in crystallization, Process Analytical Technology (PAT), continuous manufacturing, and digitization will benefit CMAC and its members, as a mechanism to develop CMC technologies of the future, with an industrial focus.

Having long been at the forefront of innovation in the pharmaceutical sector, as a Translation to Industry Collaborator, Aji Bio-Pharma will play an important role in unlocking the research potential and impact to both patients and industry.

Geert Schelkens, R&D Manager Early Phase API and Technology Development at Ajinomoto Bio-Pharma Services, stated,

“We are thrilled to join the CMAC-consortium, as CMAC is a world-renowned center for crystallization and formulation studies, and an innovator in the field of digitization. Our collaboration may help CMAC in developing solutions for commercial manufacture while we as a company aim to expand our knowledge and expertise in these domains.”

The collaboration with Aji Bio-Pharma reflects CMAC’s ongoing commitment to innovation and excellence. By working together, both organizations aim to accelerate impact within the industry and healthcare.

Massimo Bresciani, CMAC Industry Director, added,

“Ajinomoto Bio-Pharma Services, a leading CDMO, brings a wealth of experience and expertise in commercial pharmaceutical manufacturing. As a new addition to CMAC’s industry portfolio partnership, Ajinomoto offers a fresh perspective through its CDMO capabilities. With CMAC strengthening its commitment to industry leadership and expanding its research and innovation portfolio, Ajinomoto’s involvement will significantly enhance our research capabilities and accelerate the translation of advanced manufacturing solutions to the industry.”

For more information on the Aji Bio-Pharma partnership with CMAC, or to find out more about membership, please contact:

Rebekah Russell, CMAC Industry Relationship Manager

industry@cmac.ac.uk